Patrick Yeramian

Corporate Officer/Principal bei Dlx Therapeutics L L C

Vermögen: 353 641 $ am 31.05.2024

66 Jahre

29 Beziehungen

Health Technology

Consumer Services

Commercial Services

Aktive Positionen von Patrick Yeramian

Unternehmen	Position	Beginn	Ende
Dlx Therapeutics L L C	Corporate Officer/Principal	01.01.2018	-

Karriereverlauf von Patrick Yeramian

Ehemalige bekannte Positionen von Patrick Yeramian

Unternehmen	Position	Beginn	Ende
AMYLYX PHARMACEUTICALS, INC.	Technik-/Wissenschafts-/F&E-Leiter	01.03.2019	28.11.2023
BIOVIE INC.	Technik-/Wissenschafts-/F&E-Leiter	01.11.2018	01.11.2021
Kantum Pharma, Inc. Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH.	Technik-/Wissenschafts-/F&E-Leiter	01.03.2017	01.03.2019
MARKER THERAPEUTICS, INC.	Technik-/Wissenschafts-/F&E-Leiter	01.02.2015	01.01.2017
Tapimmune, Inc.	Technik-/Wissenschafts-/F&E-Leiter	01.02.2015	01.01.2017
Vaccine & Gene Therapy Institute of Florida Corp. Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Vaccine & Gene Therapy Institute of Florida Corp. provides research services. The non-profit company is based in Port Saint Lucie, FL.	Technik-/Wissenschafts-/F&E-Leiter	01.10.2011	01.02.2015
Viragen, Inc. Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL.	Technik-/Wissenschafts-/F&E-Leiter	01.06.1998	01.06.2001
G.D. Searle LLC	Corporate Officer/Principal	01.06.1993	01.06.1998
░░░░░░░ ░░░░	░░░░░ ░░░░░░░░░░░░ ░░░░░░░	-	-

Ausbildung von Patrick Yeramian

Universite Paris Est Creteil Val De Marne	Doctorate Degree
Rutgers Business School	Masters Business Admin

Statistik

International

Vereinigte Staaten	12
Frankreich	3

Operativ

Chief Tech/Sci/R&D Officer	8
Corporate Officer/Principal	2
Doctorate Degree	1

Sektoral

Health Technology	6
Consumer Services	4
Commercial Services	3

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Unternehmensverbindungen

Börsennotierte Unternehmen	4
PFIZER, INC.	Health Technology
MARKER THERAPEUTICS, INC.	Health Technology
BIOVIE INC.	Health Technology
AMYLYX PHARMACEUTICALS, INC.	Health Technology

Private Unternehmen	7
Viragen, Inc. Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL.	Health Technology
Université de Paris XI Paris Sud	Consumer Services
G.D. Searle LLC
Vaccine & Gene Therapy Institute of Florida Corp. Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Vaccine & Gene Therapy Institute of Florida Corp. provides research services. The non-profit company is based in Port Saint Lucie, FL.	Commercial Services
Kantum Pharma, Inc. Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH.	Commercial Services
Dlx Therapeutics L L C
Tapimmune, Inc.

Sehen Sie sich die Unternehmensverbindungen an